Circulogene Announces Exclusive Commercial Launch of LungLifeAI® for Indeterminate Pulmonary Nodule Assessment

PENSACOLA, Fla., May 13, 2025 /PRNewswire/ -- Circulogene is excited to announce the exclusive commercial launch of LungLifeAI®, a breakthrough AI-driven blood-based test designed to improve clinical decision-making in patients with indeterminate pulmonary nodules (IPNs) detected through CT scans.

When a lung nodule is discovered on a CT scan, deciding whether to proceed with a biopsy—especially for nodules smaller than 2 cm—can be difficult. LungLifeAI® helps close this gap by delivering high-performance molecular biomarker analysis to support informed biopsy decisions. Clinically validated, LungLifeAI® offers an 80% Positive Predictive Value (PPV), 77% sensitivity, and 74% specificity, enabling earlier and more accurate malignancy assessment.

Using a simple blood collection kit—with mobile phlebotomy options available—LungLifeAI® streamlines the diagnostic process for patients and providers. The test uses advanced AI to analyze chromosomal signal patterns in thousands of cells, offering deep molecular insight into nodule behavior and risk.

"Our physicians need greater clarity when assessing patients with indeterminate pulmonary nodules," said Mike Mullen, CEO of Circulogene. "LungLifeAI® complements our OncoGenLDx tumor profiling test by providing actionable insight when CT imaging isn't enough. With a simple blood draw, we help physicians determine which small nodules require biopsy for a timely treatment plan."

For more information, visit www.circulogene.com or explore LungLifeAI® at www.lunglifeAI.com.

About Circulogene

Circulogene is a precision diagnostics company delivering rapid, actionable results through advanced liquid biopsy technology. Our CAP and CLIA-certified lab provides molecular testing solutions to help clinicians personalize cancer treatment and track disease progression. Headquartered in Birmingham, Alabama, Circulogene supports oncologists and healthcare systems with fast turnaround, broad genomic coverage, and a commitment to improving outcomes through science and service.

Learn more at www.circulogene.com

SOURCE Circuologene